
- Annual Net Income: Wantai Bio reported a net income of 106.2 million yuan for the fiscal year.
- Total Revenue: The company achieved a total revenue of 2.25 billion yuan.
- Stock Ratings Overview: Analysts’ opinions on Wantai Bio’s stock include:
- 1 Buy recommendation
- 1 Hold recommendation
- 1 Sell recommendation
A look at Beijing Wantai Biological Phar Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is set for a positive long-term outlook, according to Smartkarma Smart Scores. The company’s resilience score is notably high, indicating strong stability even in challenging market conditions. This suggests that Beijing Wantai Biological Phar is well-positioned to weather uncertainties and sustain its operations over time. Additionally, the growth score of 3 reflects moderate potential for future expansion and development within the industry.
Although Beijing Wantai Biological Phar‘s value and dividend scores are lower, the overall outlook remains optimistic with a momentum score of 2. This indicates a stable performance trajectory and potential opportunities for growth. With a diversified portfolio of medical products, including diagnostic reagents, vaccines, and equipment, Beijing Wantai Biological Pharmacy Enterprise is well-equipped to capitalize on emerging trends in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars